Tagged with R

Ukraine Igor Bondarenko of Ukraine’s Dnipro State Medical University, Evgeny Levenko from clinical trials company, ARENSIA, and Olena Popova from IQVIA offer their perspectives on maintaining quality and ensuring participant protection in clinical trials in Ukraine during wartime.   The ongoing war places unprecedented pressure on the healthcare system and clinical…

Rare Diseases With February’s Rare Disease Day behind us, it can be easy to forget the impact of these diseases on individuals, their families and care givers, and our communities throughout the other 11 months of the year. But if we – in healthcare, in government and in academia – are to…

Argentina Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful strategy predicated on customising its offering to each country and balancing local management autonomy with a strong company culture.  …

China John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With his entrepreneurial background and knowledge of China and its life sciences ecosystem, Oyler has led the company through its consolidation…

Belgium Belgium’s drug reimbursement system has become increasingly lengthy and complex, compromising patient access to innovative medicines. The roadmap recently presented by the Minister of Health and the Belgian National Institute for Health and Disability Insurance (INAMI) proposes a series of measures to speed up access, limit the duration of reimbursement…

Spain A roundup of the latest news from Spanish pharma, including Almirall’s earnings forecast for 2023; stock price rise and layoffs at Grifols; PharmaMar’s first European approval for its lurbinectedin treatment of metastatic Small Cell Lung Cancer and Esteve’s launch of the first inhaled rescue treatment for Parkinson’s patients.   Spain’s…

Saudi Arabia Under Saudi Arabia’s Vision 2030 plan, the country has been activating the private sector’s participation in its healthcare transformation, advancing the public-private partnership (PPP) model to step up the rollout of new and more efficient healthcare infrastructures. After issuing a string of EOIs, the Kingdom’s first hospital PPP project has…

Colombia Tecnoquímicas recently invested over USD 250 million in its Colombian manufacturing plants, signifying the company’s continuing faith in its home market. Executive Vice-President Emilio Sardi Aparicio outlines the regulatory and access landscape in Colombia today, how the firm’s international footprint within Latin America has evolved, and its approach to the…

Greece Spyridon Gkikas outlines how GE HealthCare’s global transformation is playing out in Greece as well as the opportunities and challenges of bringing cutting-edge medical technology into the Greek healthcare system.   EU Recovery and Resilience Funding (RRF) is coming online, creating an opportunity for Greece to improve its healthcare system,…

South Korea As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top CDMO organizations, with revenues of USD 1.21 billion in 2021, is no exception. In response to increased demand, the firm…

Germany While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team in place. Former Roche Pharma head Bill Anderson is yet to lay out his strategic priorities as CEO of Bayer…

UAE As a part of its continued digitalisation efforts, the United Arab Emirates (UAE) has launched the region’s first pharmaceutical track-and-trace system, Tatmeen. With the new system, which will monitor each stage of drug production, the country aims to boost transparency, eliminate the sale of counterfeit medicines, build trust in the…